Idelalisib is a selective PI3Kδ (phosphoinositide 3-kinase delta) inhibitor used in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma. It works by blocking PI3Kδ signaling, inhibiting malignant B-cell proliferation and survival. Idelalisib API is manufactured under GMP-compliant conditions and is suitable for oral solid dosage formulations, including tablets

Idelalisib API is manufactured and supplied by Artis Biotech | ASTANDARDS, ensuring high purity, consistent quality, and regulatory-compliant specifications. Our APIs are produced using validated processes and are suitable for research, development, and pharmaceutical manufacturing applications.